Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians

To evaluate perioperative morbidity and mortality rate, a 3-year recurrence-free survival, and cancer-specific mortality rate in patients older than 80 years undergoing robot-assisted radical cystectomy (RARC). We retrospectively collected data of 155 consecutive patients who received RARC for muscl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of endourology 2016-07, Vol.30 (7), p.792-798
Hauptverfasser: De Groote, Ruben, Gandaglia, Giorgio, Geurts, Nicolas, Goossens, Marijn, Pauwels, Elisabeth, D'Hondt, Frederiek, Gratzke, Christian, Fossati, Nicola, De Naeyer, Geert, Schatteman, Peter, Carpentier, Paul, Novara, Giacomo, Mottrie, Alexandre
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To evaluate perioperative morbidity and mortality rate, a 3-year recurrence-free survival, and cancer-specific mortality rate in patients older than 80 years undergoing robot-assisted radical cystectomy (RARC). We retrospectively collected data of 155 consecutive patients who received RARC for muscle-invasive or high-risk nonmuscle-invasive urothelial carcinoma of the bladder between 2003 and 2014 at a high-volume robotic center. Diversion was performed intra- or extracorporeally according to the surgeon's preferences. Complications were graded according to the Clavien-Dindo system. Logistic regression analyses were used to assess the impact of age on postoperative outcomes. Of 155 consecutive patients, 22 (14.2%) patients were 80 years or older. Octogenarians did not significantly differ from younger patients in ASA score (p = 0.4) and Charlson comorbidity index (p = 0.4). Prevalence of any grade and high-grade complications was similar in both groups (all p ≥ 0.6). Older patients had a significantly higher pathologic tumor grade (p = 0.04) and a lower use of pelvic lymphadenectomy (p 
ISSN:0892-7790
1557-900X
DOI:10.1089/end.2016.0050